- Topic
38k Popularity
19k Popularity
45k Popularity
17k Popularity
43k Popularity
19k Popularity
7k Popularity
4k Popularity
97k Popularity
29k Popularity
- Pin
- 🎊 ETH Deposit & Trading Carnival Kicks Off!
Join the Trading Volume & Net Deposit Leaderboards to win from a 20 ETH prize pool
🚀 Climb the ranks and claim your ETH reward: https://www.gate.com/campaigns/site/200
💥 Tiered Prize Pool – Higher total volume unlocks bigger rewards
Learn more: https://www.gate.com/announcements/article/46166
- 📢 ETH Heading for $4800? Have Your Say! Show Off on Gate Square & Win 0.1 ETH!
The next bull market prophet could be you! Want your insights to hit the Square trending list and earn ETH rewards? Now’s your chance!
💰 0.1 ETH to be shared between 5 top Square posts + 5 top X (Twitter) posts by views!
🎮 How to Join – Zero Barriers, ETH Up for Grabs!
1.Join the Hot Topic Debate!
Post in Gate Square or under ETH chart with #ETH Hits 4800# and #ETH# . Share your thoughts on:
Can ETH break $4800?
Why are you bullish on ETH?
What's your ETH holding strategy?
Will ETH lead the next bull run?
Or any o
- 🧠 #GateGiveaway# - Crypto Math Challenge！
💰 $10 Futures Voucher * 4 winners
To join:
1️⃣ Follow Gate_Square
2️⃣ Like this post
3️⃣ Drop your answer in the comments
📅 Ends at 4:00 AM July 22 (UTC)
- 🎉 #Gate Alpha 3rd Points Carnival & ES Launchpool# Joint Promotion Task is Now Live!
Total Prize Pool: 1,250 $ES
This campaign aims to promote the Eclipse ($ES) Launchpool and Alpha Phase 11: $ES Special Event.
📄 For details, please refer to:
Launchpool Announcement: https://www.gate.com/zh/announcements/article/46134
Alpha Phase 11 Announcement: https://www.gate.com/zh/announcements/article/46137
🧩 [Task Details]
Create content around the Launchpool and Alpha Phase 11 campaign and include a screenshot of your participation.
📸 [How to Participate]
1️⃣ Post with the hashtag #Gate Alpha 3rd - 🚨 Gate Alpha Ambassador Recruitment is Now Open!
📣 We’re looking for passionate Web3 creators and community promoters
🚀 Join us as a Gate Alpha Ambassador to help build our brand and promote high-potential early-stage on-chain assets
🎁 Earn up to 100U per task
💰 Top contributors can earn up to 1000U per month
🛠 Flexible collaboration with full support
Apply now 👉 https://www.gate.com/questionnaire/6888
Rongchang Bio responds to Pfizer's $200 million impairment of Vidisutuximab: Pfizer's conclusion is based on market competition environment.
On February 7th, Jinshi Data reported that Rongchang Biology responded to the reporter's inquiry about the devaluation of its vedolizumab (RC48) by its partner Pfizer, which amounted to a reduction of 200 million US dollars. Rongchang Biology stated that this devaluation is due to changes in the market competitive environment compared to the time of the transaction, and some indications for vedolizumab have not progressed as expected, resulting in a decrease in expected value compared to the transaction time. This conclusion was made by Pfizer based on its judgment of the market competitive environment. Previously, in August 2021, Rongchang Biology authorized the overseas rights of its HER2ADC (antibody-drug conjugate) vedolizumab to ADCleading company Seagen. In 2023, Seagen was acquired by Pfizer. Currently, Pfizer is advancing the indication of vedolizumab for urothelial carcinoma overseas.